physioneal 40 glucose 1,36 % w/v/13,6 mg/ml
baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i
physioneal 40 glucose 2,27 % w/v/22,7 mg/ ml
baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i
physioneal 40 glucose 3,86 % w/v/38,6 mg/ ml
baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i
physioneal 35 clear-flex glucose 13,6 mg/ml
baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i
physioneal 40 clear-flex glucose 38,6 mg/ml
baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i
physioneal 40 clear-flex glucose 22,7 mg/ml
baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i
physioneal 40 clear-flex glucose 13,6 mg/ml
baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i
physioneal 35 clear-flex glucose 38,6 mg/ml
baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i
physioneal 35 clear-flex glucose 22,7 mg/ml
baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologiká - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.